Jpmorgan Chase & CO Vaxxinity, Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.62 - $0.86 $10,569 - $14,661	17,048 Added 61.2%	44,902 $32,000
Q4 2023 Feb 12, 2024	BUY	$0.7 - $1.31 $160 - $299	229 Added 0.83%	27,854 $23,000
Q3 2023 Nov 14, 2023	SELL	$1.25 - $3.0 $8,063 - $19,353	-6,451 Reduced 18.93%	27,625 $37,000
Q2 2023 Aug 11, 2023	BUY	$1.73 - $2.79 $58,757 - $94,759	33,964 Added 30325.0%	34,076 $85,000
Q1 2023 May 11, 2023	BUY	$1.43 - $4.24 $160 - $474	112 New	112 $0

469K

Ticker VAXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 112,150,000
Market Cap $1.12M
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.